Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

DCTH | Delcath Systems, Inc.

Index- P/E- EPS (ttm)-3.31 Insider Own1.50% Shs Outstand15.28M Perf Week-12.42%
Market Cap67.43M Forward P/E- EPS next Y-0.84 Insider Trans14.18% Shs Float14.97M Perf Month-24.50%
Income-34.90M PEG- EPS next Q-0.52 Inst Own18.90% Short Float / Ratio6.40% / 0.43 Perf Quarter-22.68%
Sales2.60M P/S25.94 EPS this Y-14.70% Inst Trans-2.20% Short Interest0.96M Perf Half Y-7.76%
Book/sh-0.02 P/B- EPS next Y60.70% ROA-155.30% Target Price18.80 Perf Year16.85%
Cash/sh0.89 P/C4.65 EPS next 5Y15.00% ROE570.80% 52W Range2.34 - 7.99 Perf YTD15.56%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-47.93% Beta0.75
Dividend %- Quick Ratio1.50 Sales past 5Y0.00% Gross Margin69.50% 52W Low77.78% ATR0.40
Employees52 Current Ratio1.80 Sales Q/Q-37.50% Oper. Margin- RSI (14)40.07 Volatility6.42% 7.92%
OptionableYes Debt/Eq- EPS Q/Q53.40% Profit Margin- Rel Volume0.18 Prev Close4.36
ShortableYes LT Debt/Eq- EarningsAug 09 AMC Payout- Avg Volume2.21M Price4.16
Recom1.60 SMA20-13.24% SMA50-10.58% SMA200-16.72% Volume396,897 Change-4.59%
Date Action Analyst Rating Change Price Target Change
Jul-26-22Resumed Canaccord Genuity Buy $17
Dec-10-21Initiated H.C. Wainwright Buy $25
Mar-09-21Initiated Canaccord Genuity Buy $24
Jan-05-21Initiated BTIG Research Buy $23
Jun-01-20Initiated Laidlaw Buy $19
Sep-14-23 09:59AM
Sep-11-23 08:00AM
Sep-05-23 04:00PM
Sep-01-23 02:07PM
Aug-29-23 08:00AM
09:10PM Loading…
Aug-14-23 09:10PM
Aug-12-23 09:02AM
Aug-09-23 05:33PM
Aug-03-23 08:30AM
Jun-21-23 04:10PM
Jun-20-23 08:30AM
Jun-07-23 04:10PM
May-12-23 08:00AM
May-09-23 09:00AM
May-03-23 08:30AM
04:30PM Loading…
Apr-03-23 04:30PM
Mar-29-23 09:41PM
Mar-27-23 03:15PM
08:20AM
08:15AM
08:10AM
Feb-16-23 08:30AM
Feb-14-23 08:49AM
Jan-30-23 08:30AM
Jan-17-23 08:00AM
Dec-16-22 04:15PM
Dec-13-22 08:30AM
Dec-08-22 08:30AM
Dec-05-22 09:00AM
Nov-09-22 04:15PM
08:00AM Loading…
Nov-08-22 08:00AM
Oct-24-22 04:05PM
Sep-01-22 04:15PM
Aug-08-22 07:45AM
Aug-05-22 08:30AM
Jul-27-22 04:30PM
04:15PM
Jul-20-22 04:10PM
Jul-18-22 08:30AM
Jun-07-22 07:06AM
Jun-06-22 04:15PM
May-10-22 07:30AM
May-09-22 08:30AM
May-02-22 03:02PM
Apr-28-22 09:00AM
Apr-08-22 09:00AM
Mar-29-22 09:00AM
Mar-25-22 07:30AM
Mar-15-22 04:30PM
Mar-10-22 09:00AM
Mar-02-22 04:01PM
Feb-22-22 09:00AM
Feb-10-22 04:30PM
Feb-07-22 04:01PM
Feb-04-22 09:00AM
Feb-03-22 04:30PM
Jan-25-22 04:01PM
Jan-07-22 09:00AM
Dec-02-21 08:00AM
Nov-30-21 08:30AM
Nov-11-21 06:06AM
Nov-09-21 07:30AM
Nov-08-21 12:49PM
09:00AM
Nov-05-21 09:00AM
Nov-02-21 03:02PM
Oct-25-21 04:01PM
Sep-02-21 09:00AM
Aug-10-21 07:30AM
Aug-09-21 07:30AM
Aug-05-21 09:00AM
Aug-03-21 03:00PM
Jul-28-21 09:00AM
Jul-08-21 11:20AM
Jul-07-21 09:00AM
Jun-23-21 09:35AM
Jun-08-21 09:00AM
Jun-07-21 12:21PM
07:30AM
Jun-03-21 09:00AM
May-26-21 09:00AM
May-24-21 06:17AM
May-11-21 08:00AM
05:45AM
May-03-21 02:33AM
Apr-30-21 04:01PM
09:00AM
Apr-21-21 08:38AM
Mar-31-21 02:55PM
08:06AM
07:45AM
07:30AM
05:45AM
Mar-24-21 04:01PM
Mar-08-21 09:00AM
Feb-11-21 09:00AM
Jan-11-21 10:56AM
Dec-11-20 10:31AM
Dec-09-20 08:00AM
Dec-08-20 04:01PM
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sylvester John RichardDirectorAug 21Buy4.8010,55050,64010,550Aug 23 11:03 AM
MICHEL GERARD JChief Executive OfficerMar 29Buy4.8419,64695,087197,235Mar 30 09:00 AM
Rosalind Advisors, Inc.DirectorDec 14Buy3.6215,21555,045459,315Dec 16 09:32 AM
SALAMON STEVEN A JDirectorDec 14Buy3.6215,21555,045455,315Dec 16 09:22 AM
MICHEL GERARD JChief Executive OfficerDec 13Buy2.9051,725150,002177,589Dec 14 03:33 PM